Welcome to our dedicated page for Re Max Hldgs SEC filings (Ticker: RMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Franchise fees, marketing funds, and agent-count metrics make RE/MAX Holdings鈥� disclosures unusually dense. Finding which segment drives cash flow鈥攐r spotting leadership鈥檚 next move鈥攐ften means sifting through hundreds of pages. Stock Titan鈥檚 AI instantly dissects every RE/MAX SEC filing, turning complex tables and footnotes into clear narratives.
Want the RE/MAX insider trading Form 4 transactions before markets react? Our platform streams RE/MAX Form 4 insider transactions real-time, flags patterns, and summarizes executive sentiment. Need the latest RE/MAX quarterly earnings report 10-Q filing? We pair the raw document with concise trend analysis so you can focus on agent growth and franchise margins, not page numbers.
Below you鈥檒l find every document filed to EDGAR鈥�10-K, 10-Q, 8-K, DEF 14A, and more鈥攚ith AI-generated highlights. Curious about dividend coverage in the RE/MAX annual report 10-K simplified or marketing-fund changes in the RE/MAX earnings report filing analysis? It鈥檚 all here, explained in plain English.
- Monitor RE/MAX executive stock transactions Form 4
- Track management updates in RE/MAX 8-K material events explained
- Review governance details in the RE/MAX proxy statement executive compensation
- Save hours by understanding RE/MAX SEC documents with AI
Whether you鈥檙e comparing quarter-over-quarter franchise sales or gauging market confidence, our AI-powered summaries and real-time alerts surface what matters鈥攕o you never miss a disclosure that moves the real-estate market.
Form 4 filing for First Busey Corp. (BUSE) 鈥� 29 Jul 2025
- Insider: Director Kevin S. Rauckman.
- Transaction date: 25 Jul 2025.
- Type: Automatic accrual of 36 common shares via dividend-equivalent rights (price = $0).
- Post-transaction holdings: 21,324 common shares held directly; plus 24,909 common shares and 250 Series A preferred shares held indirectly through the Kevin S. Rauckman Trust.
- No derivative securities were bought or sold; the entry reflects routine dividend reinvestment on deferred stock units.
The reported acquisition is de minimis relative to Rauckman鈥檚 existing stake and has no stated impact on company operations or capital structure. Investors may interpret continued accumulation鈥攁lbeit small鈥攁s a neutral-to-mildly positive signal of alignment, but the size is unlikely to influence share price.
Aclaris Therapeutics (Nasdaq: ACRS) has filed a Form 8-K to inform investors that it will host a conference call on 29 Jul 2025 to review top-line data from its Phase 2a study of ATI-2138, an oral covalent ITK/JAK3 inhibitor for moderate-to-severe atopic dermatitis. Two items are furnished: Exhibit 99.1 (investor presentation) and Exhibit 99.2 (press release). Under Reg FD, Items 7.01 and 8.01 are furnished鈥攏ot filed鈥攕o the information is not subject to Exchange Act liability nor automatically incorporated into other SEC reports.
The 8-K contains no numerical efficacy, safety, or financial metrics. Investors must consult the accompanying exhibits or join the conference call for detailed results. No changes to financial statements or previously issued guidance are included.
FAQ
What is the current stock price of Re Max Hldgs (RMAX)?
What is the market cap of Re Max Hldgs (RMAX)?
What is RE/MAX Holdings Inc?
How does RE/MAX generate revenue?
What distinguishes RE/MAX's business model?
How does RE/MAX support its agents?
What role does technology play in RE/MAX's operations?
How does the company maintain its global market presence?
What is the significance of Motto Mortgage?
How does RE/MAX contribute to local communities?
